Hungarian Egis says new law may cut profit by Ft 3-8 bln
Hungarian drug producer Egis estimates that a recent law on drug subsidies may cut its profit by Ft 3 billion to Ft 8 billion, its CEO told Világgazdaság on Wednesday.
The new law will require drug producers to pay back 12% of their turnover on state-subsidised drugs into the budget, pay a Ft 5 million annual fee per sales agent and pay for more than half of any subsidy spending overshoot in the budget. Egis CEO Péterné Gál told that the new law posed a threat to innovation within the domestic pharmaceutical industry. Gál told the paper that, as a first step, Egis had reviewed its product portfolio and decided to take out products that would no longer be economical due to a rise in costs. This may affect about 10% of Egis's portfolio, which contains 1,650 products. (portfolio.hu)
Producing journalism that is worthy of the name is a costly business. For 27 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.